These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 18422773
1. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat SF, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. BJU Int; 2008 Jun; 101(12):1513-8. PubMed ID: 18422773 [Abstract] [Full Text] [Related]
2. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Chun FK, Briganti A, Gallina A, Hutterer GC, Shariat SF, Antebie E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807 [Abstract] [Full Text] [Related]
3. Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. Chun FK, Briganti A, Antebi E, Graefen M, Currlin E, Steuber T, Schlomm T, Walz J, Haese A, Friedrich MG, Ahyai SA, Eichelberg C, Salomon G, Gallina A, Erbersdobler A, Perrotte P, Heinzer H, Huland H, Karakiewicz PI. BJU Int; 2006 Dec; 98(6):1204-9. PubMed ID: 17034506 [Abstract] [Full Text] [Related]
4. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. Gallina A, Karakiewicz PI, Chun FK, Briganti A, Graefen M, Montorsi F, Walz J, Jeldres C, Erbersdobler A, Salonia A, Suardi N, Dehò F, Schlomm T, Scattoni V, Haese A, Heinzer H, Valiquette L, Rigatti P, Huland H. BJU Int; 2007 Jun; 99(6):1404-8. PubMed ID: 17428250 [Abstract] [Full Text] [Related]
5. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database. Freedland SJ, Amling CL, Terris MK, Presti JC, Aronson WJ, Elashoff D, Kane CJ, SEARCH Database Study Group. Prostate Cancer Prostatic Dis; 2003 Jun; 6(3):261-5. PubMed ID: 12970733 [Abstract] [Full Text] [Related]
6. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy. Rodriguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L. BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921 [Abstract] [Full Text] [Related]
14. Study of prostate cancer pathologic features in Chinese populations. Chuang AY, Chang SJ, Horng CF, Tsou MH. Urology; 2007 May; 69(5):915-20. PubMed ID: 17482934 [Abstract] [Full Text] [Related]
19. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI. Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223 [Abstract] [Full Text] [Related]
20. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC. BJU Int; 2005 Jan; 95(1):34-9. PubMed ID: 15638892 [Abstract] [Full Text] [Related] Page: [Next] [New Search]